Oruka Therapeutics (NASDAQ:ORKA) Price Target Raised to $70.00 at HC Wainwright

Key Points

• HC Wainwright raised its price target on Oruka Therapeutics to $70 from $40 and kept a "buy" rating, and several other brokers have also increased targets — the consensus price target is about $68.40, implying roughly 17.49% upside.
• The stock opened around $59.58 with a market cap of $2.95 billion and a 52-week range of $7.14–$64.61, and Oruka recently beat quarterly EPS estimates (reported -$0.45 vs. -$0.61 expected).
• Oruka is a clinical-stage biotech developing a stapled peptide platform with lead candidate ONCT-01 in Phase 1, while insiders have sold shares recently (23,765 shares over three months) and institutional investors own about 56.44% of the stock.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) had its target price raised by equities research analysts at HC Wainwright from $40.00 to $70.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's target price points to a potential upside of 17.49% from the stock's previous close.

Several other research firms have also issued reports on ORKA. Leerink Partners lifted their price target on Oruka Therapeutics from $58.00 to $86.00 and gave the stock an "outperform" rating in a research report on Monday, March 16th. Barclays increased their price objective on shares of Oruka Therapeutics from $50.00 to $78.00 and gave the company an "overweight" rating in a research report on Tuesday, April 7th. Wedbush reissued an "outperform" rating and set a $45.00 price objective on shares of Oruka Therapeutics in a research report on Friday, March 13th. UBS Group increased their price objective on shares of Oruka Therapeutics from $50.00 to $75.00 and gave the company a "buy" rating in a research report on Monday, April 6th. Finally, Guggenheim reissued a "buy" rating and set a $60.00 price objective on shares of Oruka Therapeutics in a research report on Friday, March 13th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $68.40.

Oruka Therapeutics Price Performance

Shares of ORKA opened at $59.58 on Monday. The stock has a market cap of $2.95 billion, a P/E ratio of -32.03 and a beta of -0.54. The business's 50 day moving average price is $39.53 and its 200-day moving average price is $32.31. Oruka Therapeutics has a 52 week low of $7.14 and a 52 week high of $64.61.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.61) by $0.16. On average, equities analysts anticipate that Oruka Therapeutics will post -3.41 EPS for the current year.

Insider Activity at Oruka Therapeutics

In other news, CEO Lawrence Otto Klein sold 1,729 shares of the business's stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $41.30, for a total transaction of $71,407.70. Following the completion of the transaction, the chief executive officer directly owned 927,309 shares of the company's stock, valued at $38,297,861.70. The trade was a 0.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Joana Goncalves sold 7,641 shares of the business's stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $40.91, for a total transaction of $312,593.31. Following the transaction, the insider directly owned 33,377 shares of the company's stock, valued at $1,365,453.07. The trade was a 18.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 23,765 shares of company stock valued at $849,575 over the last three months. 24.69% of the stock is owned by corporate insiders.

Institutional Trading of Oruka Therapeutics

Several large investors have recently added to or reduced their stakes in ORKA. Caitong International Asset Management Co. Ltd bought a new stake in Oruka Therapeutics during the fourth quarter valued at approximately $67,000. Seven Fleet Capital Management LP bought a new stake in Oruka Therapeutics during the fourth quarter valued at approximately $159,000. Invesco Ltd. grew its position in Oruka Therapeutics by 777.1% during the fourth quarter. Invesco Ltd. now owns 143,121 shares of the company's stock valued at $4,338,000 after buying an additional 126,803 shares during the period. Virtus Investment Advisers LLC purchased a new position in Oruka Therapeutics during the fourth quarter valued at $267,000. Finally, RTW Investments LP grew its holdings in Oruka Therapeutics by 5.8% during the fourth quarter. RTW Investments LP now owns 2,058,148 shares of the company's stock valued at $62,382,000 after purchasing an additional 112,499 shares during the period. 56.44% of the stock is currently owned by institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.